PTPI Petros Pharma: Enterprise Value to EBITDA Ratio
Petros Pharmaceuticals (PTPI) generates revenue from the sale of men's health products, where patient brand loyalty ensures stable demand. The stock price action based on the EV/EBITDA metric, which currently stands at , complements data regarding the confidential delivery of prescription forms via online pharmacies. However, reliance on a single core product and challenges in transitioning to the over-the-counter segment create a certain business vulnerability.
Comprehensive metric breakdowns and analytics for petrospharma.com (PTPI)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Petros Pharmaceuticals|PTPI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Petros Pharmaceuticals, Inc.|PTPI - Company Aggregate Indebtedness|Debts to Book Capitalization Petros Pharma|PTPI - Long-Term Debt|Company Current Liabilities Petros Pharmaceuticals|Quick Liquidity petrospharma.com
- financial results and valuation multiples details:
PTPI - Final Profit|Expected Profit Petros Pharmaceuticals|PTPI - Market Cap to Earnings|Future Price to Earnings Petros Pharmaceuticals|PTPI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Petros Pharma|PTPI - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Petros Pharmaceuticals|PTPI - Earnings per one share for the last 12 months|Quarterly EPS earnings growth petrospharma.com|PTPI - Earnings per share increase in current year|Earnings growth forecast for next year Petros Pharmaceuticals
- company sales and revenue statistics:
Fundamental valuation:Petros PTPI
For the biopharmaceutical company Petros Pharmaceuticals (PTPI), which is developing a digital access platform for the Stendra brand, calculating business value relative to earnings before interest, taxes, depreciation, and amortization is critically important. This metric measures the company's ability to generate cash flow to service debt and fund capital expenditures. When analyzing the EV/EBITDA valuation multiple, an investor must distinguish between an undervalued asset and systemic solvency risks.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MNKD (MannKind Corp) - Company Value to Operating Income Before Depreciation Ratio|Amphastar - EV/EBITDA Multiple|Company Value to EBITDA Pacira Corp|SPRY (ARS Pharmaceuticals) - Enterprise Value to EBITDA Ratio|TBPH: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|TNXP - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|Total Company Value to Operating Income Before Depreciation Ratio Eupraxia Pharmaceuticals, Inc. (EPRX)|BHST: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation EXOZ (Invizyne Technologies)|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ENTX (Entera Bio)|HYFT (MindWalk Holdings) - EV/EBITDA Multiple|ABVC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPIX|EV/EBITDA Multiple Quantum BioPharma Ltd. (QNTM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen Corp FGEN|Business Value to Operating Income Before Depreciation TELO|RANI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Synergy CHC Corp (SNYR) - Enterprise Value to EBITDA Ratio|RLYB: EV/EBITDA Multiple|Lexaria Bioscience Corp. (LEXX) - EV/EBITDA Multiple|PULM (Pulmatrix Corp) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pheton (PTHL)|EV/EBITDA Multiple APM|LYRA - Company Value to EBITDA|Impact BioMedical - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple TNF Pharmaceuticals Inc. TNFA|YCBD: Enterprise Value to EBITDA Ratio|PainReform Corp - Enterprise Value to Operating Income Before Depreciation Ratio|CYTO: EV/EBITDA Multiple|LIPO - Total Company Value to Operating Income Before Depreciation Ratio|OPTN (OptiNose) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pieris Pharmaceuticals Inc (PIRS)|EV/EBITDA Multiple PROC|EV/EBITDA Multiple Qilian International Corp (QLI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|tffpharma.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
